Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer

Baysal, Hakan; Serdaroğlu, Ahmet Yusuf; Özemir, İbrahim Ali; Baysal, Begümhan; Güngör, Serkan; Erol, Cem Ilgın; Özsoy, Mehmet; Ekinci, Özgür; Ali̇moğlu, Orhan

doi:10.1016/j.jss.2022.04.063

Cited by 5 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering predefined eligibility criteria, out of these 76 articles assessed for eligibility, 62 records were excluded (40 as not in the field of interest; 15 as reviews, editorials, or letters; 6 as case reports; 1 preclinical study). After full-text examination, the remaining 14 articles were suitable for inclusion in our systematic review ( Figure 1 ) [ 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ].…”

Section: Resultsmentioning

confidence: 99%

“…In most of the included studies (71.4%), MRI scans were acquired on a 3.0 Tesla (T) system with a dedicated breast coil. Three out of fourteen studies (21.4%) used both 1.5 and 3.0 T MRI and only two used 1.5 T. One study also included contrast-enhanced US in the comparison of techniques and Tokuda et al evaluated dedicated-breast PET (dbPET) [ 22 , 28 ]. [ 18 F]FDG was the radiotracer used in every study included; PET data were acquired in a two-dimensional mode after na on-contrast CT scan from the base of the skull to the pelvis.…”

Section: Resultsmentioning

confidence: 99%

“…Very recently, Baysal and colleagues [ 22 ] evaluated the agreement between MRI and PET/CT response in 88 BC patients who underwent surgery following NAC. Tumor diameters and SUVmax were significantly decreased ( p < 0.001), with MRI being more sensitive in ER-positive and E-cadherin-negative patients, while PET/CT was more sensitive in those with HER-2 overexpression, Luminal-B, or proliferation rate >14% ( p = 0.01).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives

Caracciolo,

Castello,

Urso

et al. 2023

JCM

View full text Add to dashboard Cite

The purpose of this systematic review was to investigate the diagnostic accuracy of [18F]FDG PET/CT and breast MRI for primary breast cancer (BC) response assessment after neoadjuvant chemotherapy (NAC) and to evaluate future perspectives in this setting. We performed a critical review using three bibliographic databases (i.e., PubMed, Scopus, and Web of Science) for articles published up to the 6 June 2023, starting from 2012. The Quality Assessment of Diagnosis Accuracy Study (QUADAS-2) tool was adopted to evaluate the risk of bias. A total of 76 studies were identified and screened, while 14 articles were included in our systematic review after a full-text assessment. The total number of patients included was 842. Eight out of fourteen studies (57.1%) were prospective, while all except one study were conducted in a single center. In the majority of the included studies (71.4%), 3.0 Tesla (T) MRI scans were adopted. Three out of fourteen studies (21.4%) used both 1.5 and 3.0 T MRI and only two used 1.5 T. [18F]FDG was the radiotracer used in every study included. All patients accepted surgical treatment after NAC and each study used pathological complete response (pCR) as the reference standard. Some of the studies have demonstrated the superiority of [18F]FDG PET/CT, while others proved that MRI was superior to PET/CT. Recent studies indicate that PET/CT has a better specificity, while MRI has a superior sensitivity for assessing pCR in BC patients after NAC. The complementary value of the combined use of these modalities represents probably the most important tool to improve diagnostic performance in this setting. Overall, larger prospective studies, possibly randomized, are needed, hopefully evaluating PET/MR and allowing for new tools, such as radiomic parameters, to find a proper place in the setting of BC patients undergoing NAC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives

Caracciolo,

Castello,

Urso

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…The histological BC subtypes notoriously correlate with a different response to medical treatment. A different sensitivity in detecting pCR after NAC was found to be related to parameters such as estrogen receptor expression, on the one hand and HER-2 overexpression, luminal B, or Ki-67 proliferation >14%, on the other hand, respectively favoring MRI and PET-CT ( 33 ). Therefore, the need for radiological studies set by subtypes is progressively acknowledged ( 34 ).…”

Section: Discussionmentioning

confidence: 99%

Case report: An ultrasound-based approach as an easy tool to evaluate hormone receptor-positive HER-2-negative breast cancer in advanced/metastatic settings: preliminary data of the Plus-ENDO study

Montella,

Di Marino,

Marino

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundHormone receptor-positive tumors are unlikely to exhibit a complete pathological tumor response. The association of CDK 4/6 inhibitor plus hormone therapy has changed this perspective.Case presentationIn this study, we retrospectively reviewed the charts of patients with a diagnosis of luminal A/B advanced/metastatic tumors treated with a CDK 4/6 inhibitor-based therapy. In this part of the study, we present clinical and ultrasound evaluation. Eight female patients were considered eligible for the study aims. Three complete and five partial responses were reported, including a clinical tumor response of 50% or more in five out of nine assessed lesions (55%). All patients showed a response on ultrasound. The mean lesion size measured by ultrasound was 27.1 ± 15.02 mm (range, 6–47 mm) at the baseline; 16.08 ± 14.6 mm (range, 0–40 mm) after 4 months (T1); and 11.7 ± 12.9 mm (range, 0–30 mm) at the 6 months follow-up (T2). Two patients underwent surgery. The radiological complete response found confirmation in a pathological complete response, while the partial response matched a moderate residual disease.ConclusionThe evaluation of breast cancer by ultrasound is basically informative of response and may be an easy and practical tool to monitor advanced tumors, especially in advanced/unfit patients who are reluctant to invasive exams.

show abstract

“…Ultrasound, mammography, MRI, and other imaging examinations are central to the screening, diagnosis, staging, and e cacy monitoring of breast cancer [6,7]. Numerous studies have shown that imaging examinations can also predict the tumor after NAC and the pCR of axillary lymph nodes and has excellent diagnostic e cacy [8][9][10][11]. The response evaluation criterion in solid tumor (RECIST) describes the e cacy before and after NAC as evaluated by ultrasound, MRI, and mammography measure the maximum diameter of the target lesion tumor [12,13].…”

Section: Introductionmentioning

confidence: 99%

Deep transfer learning radiomics based on two-dimensional ultrasound for predicting the efficacy of neoadjuvant chemotherapy in breast cancer

Wang

Zhao

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose We investigate the predictive value of a comprehensive model based on preoperative ultrasound radiomics, deep migration learning, and clinical features for pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) for the breast cancer. Methods We enrolled 211 patients with pathologically confirmed the breast cancer who underwent NAC. The patients were randomly divided into the training set and the validation set in the ratio of 7:3. The deep learning and radiomics features of pre-treatment ultrasound images were extracted, and the random forest recursive elimination algorithm and the least absolute shrinkage and selection operator were used for feature screening and DL-Score and Rad-Score construction. According to multiple logistic regression, independent clinical predictors, DL-Score, and Rad-Score were selected to construct the comprehensive prediction model DLR + C. The performance of the model was evaluated in terms of its predictive effect, calibration ability, and clinical practicability. Result Compared to the clinical, radiomics (Rad-Score), and deep learning (DL-Score) models, the DLR + C accurately predicted the pCR status, with an area under the curve (AUC)of 0.906 (95% CI: 0.871–0.935) in the training set and 0.849 (95% CI: 0.799–0.887) in the validation set, with good calibration ability (Hosmer-Lemeshow: P > 0.05). Moreover, decision curve analysis confirmed that the DLR + C had the highest clinical value among all models. Conclusion The comprehensive model DLR + C based on ultrasound radiomics, deep transfer learning, and clinical features can effectively and accurately predict the pCR status of breast cancer after NAC, which is conducive to assisting clinical personalized diagnosis and treatment plan.

show abstract

Comparison of Magnetic Resonance Imaging With Positron Emission Tomography/Computed Tomography in the Evaluation of Response to Neoadjuvant Therapy of Breast Cancer

Cited by 5 publications

References 30 publications

Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives

Comparison of MRI vs. [18F]FDG PET/CT for Treatment Response Evaluation of Primary Breast Cancer after Neoadjuvant Chemotherapy: Literature Review and Future Perspectives

Case report: An ultrasound-based approach as an easy tool to evaluate hormone receptor-positive HER-2-negative breast cancer in advanced/metastatic settings: preliminary data of the Plus-ENDO study

Deep transfer learning radiomics based on two-dimensional ultrasound for predicting the efficacy of neoadjuvant chemotherapy in breast cancer

Contact Info

Product

Resources

About